[Psychomotility, extrapyramidal syndrome and mode of action of neuroleptic therapies; chlorpromazine, reserpine and prochlorperazine].
D014150:Antipsychotic Agents; D001480:Basal Ganglia Diseases; D002746:Chlorpromazine / Q000627:therapeutic use*; D004194:Disease; D005116:Extrapyramidal Tracts; D006801:Humans; D001523:Mental Disorders / Q000628:therapy*; D010300:Parkinson Disease / Q000209:etiology*; D010640:Phenothiazines / Q000031:analogs & derivatives; D011346:Prochlorperazine; D011613:Psychotherapy; D012110:Reserpine / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D010640:Phenothiazines; D012110:Reserpine; C031637:phenothiazine; D002746:Chlorpromazine; D011346:Prochlorperazine
CHLORPROMAZINE/therapeutic use; EXTRAPYRAMIDAL TRACTS/diseases; MENTAL DISORDERS/therapy; PARALYSIS AGITANS/etiology and pathogenesis; PHENOTHIAZINE/related compounds; RESERPINE/therapeutic use
Psychomotilität, extrapyramidale Syndrome und Wirkungsweisen neuroleptischer Therapien; Chlorpromazine, Reserpine, Proclorperazine.